COVID-19 study to be conducted in Russia and Ukraine

Global Clinical Trials has been awarded a randomized, double-blind, placebo-controlled phase II clinical study in patients with COVID-19, SARS CoV-2 infection. GCT will manage project in Ukraine and Russia targeting to enroll about 50 hospitalized subjects in 1,5 months. The objective of the trial it to evaluate the drug safety and its effect on inflammation.

“On behalf of the Global Clinical Trials team, we are grateful and enthusiastic to contribute to the development of treatments against the Coronavirus Disease. I look forward to seeing what this project can bring to the global blueprint for patients affected by the virus,” – Dr. Eugene Selivra, GCT CEO.

The study has been contracted out to GCT this month, and our team is progressing quickly with start-up activities to ensure accelerated submission for this highly prioritized trial.